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Aim: MULTIPRAC was designed to provide insights into the use and outcomes associated 
with prehospital initiation of antiplatelet therapy with either prasugrel or clopidogrel in the 
context of primary percutaneous coronary intervention. After a previous report on efficacy and 
safety outcomes during hospitalization, we report here the 1-year follow-up data, including 
cardiovascular (CV) mortality.
Methods and results: MULTIPRAC is a multinational, prospective registry of patients with 
ST-elevation myocardial infarction (STEMI) from 25 hospitals in nine countries, all of which 
had an established practice of prehospital start of dual antiplatelet therapy in place. The key 
outcome was CV death at 1 year. Among 2,036 patients followed-up through 1 year, 49 died 
(2.4%), 10 during the initial hospitalization and 39 within 1 year after hospital discharge. The 
primary analysis was based on the P2Y
12
-inhibitor, used from prehospital loading dose through 
hospital discharge. Prasugrel (n=824) was more commonly used than clopidogrel (n=425). The 
observed 1-year rates for CV death were 0.5% with prasugrel and 2.6% with clopidogrel. After 
adjustment for differences in baseline characteristics, treatment with prasugrel was associated 
with a significantly lower risk of CV death than treatment with clopidogrel (odds ratio 0.248; 
95% confidence interval 0.06–0.89).
Conclusion: In STEMI patients from routine practice undergoing primary angioplasty, who 
were able to start oral antiplatelet therapy prehospital, treatment with prasugrel as compared to 
clopidogrel was associated with a lower risk of CV death at 1-year follow-up.
Keywords: upstream treatment, P2Y
12
-inhibitor, dual antiplatelet therapy, primary percutaneous 
coronary intervention, observational
Introduction
A cornerstone of medication-based treatment of ST-segment elevation myocardial 
infarction (STEMI) is dual antiplatelet therapy (DAPT) with acetylic salicylic acid plus 
a P2Y
12
-inhibitor, in addition to anticoagulation. The P2Y
12
-inhibitor should be admin-
istered at the time of first medical contact.1 The rationale for prehospital application of 
the loading dose (LD) is based on short period to primary percutaneous coronary inter-
vention (PCI) in combination with pathophysiological alterations or co-medication with 
morphine, both known to cause delay in absorption/ metabolization of orally administered 
drugs applied in the acute phase of STEMI. Accordingly, the onset of the antiplatelet 
effect of oral P2Y
12
-inhibitors has been reported to be delayed in this setting, and this 
delay is more pronounced with clopidogrel2 than with prasugrel or ticagrelor.3
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When looking at clopidogrel only, there is evidence from 
registries4,5 and from a meta-analysis of randomized clini-
cal trials (RCTs) and registries6 that suggest that in STEMI 
patients, initiation of DAPT with clopidogrel before PCI 
treatment (primary PCI), compared with initiation at the time 
of PCI, is associated with lower mortality.
For the newer, faster acting and more potent P2Y
12
-inhibitors 
prasugrel and ticagrelor, prehospital versus in-hospital initia-
tion in the primary PCI setting has been formally tested in 
only one RCT with ticagrelor in both arms. The ATLANTIC 
trial, however, failed to show a benefit from prehospital initia-
tion of ticagrelor when measured either by the two co-primary 
surrogate endpoints, or by mortality.7
It is less clear whether the benefit seen with early initiation 
of clopidogrel is of clinical relevance under today’s clinical 
conditions, as prasugrel or ticagrelor should be the preferred 
treatment over clopidogrel, if not contraindicated.1
The European MULTIPRAC registry allows for a com-
parison between different P2Y
12
-inhibitors in the setting of 
administration at first medical contact and with real-world 
treatment delays. After an earlier report of outcomes for the 
initial hospitalization,8 which showed modest and nonsignifi-
cant differences in clinical outcomes, here we report the 1-year 
follow-up data, including cardiovascular (CV) mortality.
Methods
Design
The design of the “MULTInational non-interventional study 
of patients with ST-segment elevation myocardial infarction 
treated with PRimary Angioplasty and Concomitant use of 
upstream antiplatelet therapy with prasugrel or clopidogrel 
(MULTIPRAC)” registry has been described in detail earlier.8 
In brief, MULTIPRAC was a prospective noninterventional 
study, performed in compliance with the Declaration of 
Helsinki and local legislation. The primary ethics committee 
approval was obtained under the number 2011/141 by the 
Comité Etico de Investigacion, Clinica de Galicia Edificio 
Administrativo de San Lazaro, Santiago de Compostela 
(Spain), and further local ethics committee approvals were 
obtained. All patients provided written informed consent 
prior to documentation. The study has been registered in 
the German Clinical Trials Register (DRKS), an approved 
Primary Register in the World Health Organization (WHO) 
network (DRKS00003378).
Between June 2011 and June 2013, 25 PCI centers from 
nine countries, all of which had an established practice of 
prehospital treatment with one of the two P2Y
12
-inhibitors 
available at the time the registry started, namely clopidogrel 
or prasugrel included consecutive patients arriving alive in 
the hospital catheterization laboratory. Their treatment was 
documented from symptom onset through hospital discharge, 
with a 1-year follow-up for vital status.
The enrollment criteria were age $18 years, upstream 
thienopyridine LD (ie, 60 mg prasugrel or 300/600 mg 
clopidogrel) immediately after STEMI diagnosis and prior 
to/during ambulance transport to a catheterization laboratory 
hospital for primary PCI, written informed consent, and no 
enrollment in a competing clinical study.
At 1-year follow-up, the investigators were asked to report 
mortality only, an endpoint that can be collected at high rate 
of completeness, and which is inclusive of the most severe 
sequelae from re-infarction or bleeding occurring during 
follow-up. The source of information (eg, patient charts, 
physician, relatives, patient), death (yes, no, unknown) 
with date, and primary cause of death as indicated by the 
investigators (CV death, non-CV death, and presumed CV 
death, defined as the composite of confirmed CV death and 
death not further specified) were collected. Follow-up was 
99.2% complete.
The primary analysis of 1-year CV mortality from hospi-
tal admission through 1 year was based on the P2Y
12
-inhibitor 
used from the prehospital LD until hospital discharge. This 
defined three groups of patients: a prasugrel group, a clopi-
dogrel group, and a group of patients switched in-hospital 
from clopidogrel to prasugrel. The remaining 243 “other” 
patients were excluded from this analysis as they constituted a 
diverse group with complex switching patterns, even includ-
ing switching to ticagrelor, at the end of the study period 
when this drug became available (Figure 1).
A secondary analysis grouped patients by the P2Y
12
-inhibitor 
(prasugrel, clopidogrel, ticagrelor) prescribed at discharge, and 
deaths were considered between discharge and the 1-year follow-
up. This sample included a smaller group of patients (n=156) 
switched in-hospital to ticagrelor, mostly from clopidogrel. For 
these patients switched to ticagrelor and the 35 patients who 
had no P2Y
12
-inhibitor prescribed at discharge, no statistical 
comparisons with the clopidogrel group were made, due to the 
small number of patients. Results are provided separately for 
CV death, all-cause death, and presumed CV death.
Continuous variables are reported as mean ± standard 
deviation (SD) or medians with interquartile range. The main 
comparison was between prasugrel and clopidogrel groups, 
with t-test (when normally distributed) or the two-tailed Mann–
Whitney U test applied. Qualitative (binary or  categorical) 
variables are reported as absolute and  percentage numbers, and 
were compared by means of a logistic regression model.
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Death rates in the various groups were compared with 
logistic regression models, as there was some uncertainty 
with regard to timing of death in a few cases. These models 
contained treatment as main effects, and were adjusted for dif-
ferences between the treatment groups. The primary analysis 
was done on the basis of CV deaths; additional analyses were 
performed on all-cause and presumed CV deaths.
When adjusting for differences in baseline characteristics, 
the following covariates were used based on observed differ-
ences (P,0.10) between prasugrel and clopidogrel groups: 
age (years), sex, center, time from symptom onset to start 
of PCI (minutes), glycoprotein inhibitor use  prehospital and 
in-hospital, number of diseased vessels (0 or 1, $2),  medical 
history of non-STEMI or STEMI, PCI, stroke, or transient 
ischemic attack (TIA), congestive heart failure, peripheral 
vascular disease, chronic renal impairment, and diabetes 
mellitus.
Results of all comparisons performed using logistic 
regression models are reported as odds ratio (OR) and 95% 
confidence intervals (CIs), with P-values.
All statistical analyses were performed with SAS version 
9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Pre- and in-hospital antiplatelet therapy
Patient flow and disposition are displayed in Figure 1. Of 
the 2,036 patients eligible for this analysis, 927 (45.5%) 
received prasugrel prehospital loading and 1,109 (54.5%) 
received clopidogrel prehospital loading. Prehospital load-
ing with clopidogrel was predominantly administered at 
the 600 mg dose (84%), and prasugrel loading was almost 
exclusively administered at the 60 mg dose (99.5%). A total 
of 15.7% of patients were on chronic acetylic salicylic acid 
with a median dose of 100 mg and 2.7% were on chronic 
clopidogrel. Pre- and in-hospital administration of GPIIb/IIIa 
inhibitors was overall reported in 34.2% of patients, with a 
trend toward more frequent use in the prasugrel group versus 
the clopidogrel group (35.7% vs 30.6%, P=0.072).
Reloading with a P2Y
12
-inhibitor in the catheterization 
laboratory was more frequently done with prasugrel than 
with clopidogrel (20.2% vs 2.3%). Before discharge, almost 
20% of all patients were switched from one to another P2Y
12
-
inhibitor. The most frequent switching was from clopidogrel 
to prasugrel or to ticagrelor (48.9% and 11.8% of those 
initially loaded with clopidogrel, respectively). Switching 
from prasugrel to one of the other P2Y
12
-inhibitors was less 
frequent in prasugrel-loaded patients (8.2% to clopidogrel 
and 2.8% to ticagrelor, for a total of 11.0%).
The primary analysis was based on the P2Y
12
-inhibitor 
used from prehospital LD until discharge from the hospital 
(prasugrel, n=824; clopidogrel, n=425; switched in-hospital 
from clopidogrel to prasugrel, n=544).
One-year follow-up
The follow-up information was mainly extracted from patient 
charts (40.6%) or obtained from the patient (38.4%), and less 
frequently from a patient’s relative (11.6%) or the treating 
physician (8.7%). Median time between PCI and the 1-year 
follow-up visit was 360 days (interquartile range: 343–375), 
with no difference between the prasugrel and clopidogrel 
groups (median, 360 vs 362 days). Of the 2,026 patients 
discharged from the hospital, a total of 1,344 (66.3%) 
Enrolled
n=2,095a
Excluded from analysis
n=43b
Eligible for analysis
n=2,052
Eligible for 1-year mortality follow-up
n=2,036c
Lost to follow-up n=15
Informed consent
withdrawn n=1
Other
n=243 (11.9%)
Switch from C to P
n=544 (26.7%)
Clopidogrel
n=425 (20.9%)
Prasugrel
n=824 (40.5%)
Died in-hospital =2
Discharged =241
Died after discharge =9
Died in-hospital =1
Discharged =543
Died after discharge =3
Died in-hospital =3
Discharged =422
Died after discharge =18
Died in-hospital =4
Discharged =820
Died after discharge =9
Figure 1 Patient flow and disposition.
Notes: aDifferent from baseline data reported earlier, as one patient needed to be withdrawn (informed consent form was lost). bThirty-one missed loading dose, ten 
received loading dose in catheterization laboratory, one vomited after loading dose, one had no initial sTeMi diagnosis. cincludes ten patients who died in-hospital and 2,026 
patients discharged from hospital with available 1-year follow-up information.
Abbreviations: c, clopidogrel; P, prasugrel; sTeMi, sT-elevation myocardial infarction.
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Table 1 Baseline characteristics, by P2Y12-inhibitor treatment from loading dose through hospital discharge
Characteristic All patients, 
n=2,036  
(100.0%)
Prasugrel, 
n=824  
(40.5%)
Clopidogrel, 
n=425  
(20.9%)
Switch from  
clopidogrel to  
prasugrel, 
n=544 (26.7%)
P-value,  
prasugrel vs 
clopidogrel
age, years, mean (sD) 60.8 (12.1) 57.1 (10.1) 66.9 (13.3) 58.3 (10.2) ,0.001a
sex, female 447 (22.0) 140 (17.0) 139 (32.7) 99 (18.2) ,0.001b
Previous Mi 228 (11.2) 78 (9.5) 59 (13.9) 55 (10.1) 0.019b
congestive heart failure 48 (2.4) 12 (1.5) 13 (3.1) 11 (2.0) 0.061b
Previous Pci 184 (9.0) 65 (7.9) 48 (11.3) 44 (8.1) 0.048b
Previous caBg 29 (1.4) 8 (1.0) 9 (2.1) 4 (0.7) 0.106b
Previous stroke/Tia 82 (4.0) 11 (1.3) 33 (7.8) 5 (0.9) ,0.001b
Peripheral vascular disease 80 (3.9) 21 (2.5) 26 (6.1) 10 (1.8) 0.002b
chronic renal impairment 32 (1.6) 10 (1.2) 16 (3.8) 0 (0.0) 0.005b
Diabetes mellitus 275 (13.5) 94 (11.4) 69 (16.2) 78 (14.3) 0.017b
Killip class $ iic 112 (7.3) 37 (6.8%) 30 (9.7) 29 (5.9) 0.133b
Time from sO to start of Pci,  
median (hh:mm)
3:15 3:12 3:30 3:00 ,0.001d
Time from isD to start of Pci,  
median (hh:mm)
1:28 1:30 1:32 1:27 0.116d
no of diseased vessels ($2) 918 (45.1) 351 (42.6) 203 (47.8) 235 (43.2) 0.082b
infarct-related artery: lMca  
or laD
884 (43.4) 352 (42.7) 177 (41.6) 245 (45.0) 0.717b
Notes: Values are n (%) if not stated otherwise. P-values refer to the comparison between the clopidogrel vs prasugrel groups. astudent’s t-test, blogistic regression model, 
cinformation available from 1,538 patients, and dWilcoxon signed rank test.
Abbreviations: caBg, coronary artery bypass graft; isD, initial sTeMi diagnosis; laD, left anterior descending coronary artery; lMca, left main coronary artery; Mi, 
myocardial infarction; Pci, percutaneous coronary intervention; sD, standard deviation; sO, symptom onset; Tia, transient ischemic attack.
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Clopidogrel (n=425) Prasugrel (n=824) Switch from C to P (n=544)
5
4
3
2
1
0
All-cause death Presumed CV death CV death
n=4
n=8
n=13
n=21
n=11
n=16
n=3n=4n=4
Figure 2 Death rates from hospital admission through 1 year.
Notes: analysis is restricted to patients with documented 1-year follow-up (n=2,036).
Abbreviations: c, clopidogrel; cV, cardiovascular; P, prasugrel.
were discharged on prasugrel, 491 (24.2%) on clopidogrel, 
156 (7.7%) on ticagrelor, and 35 (1.7%) without treatment 
with a P2Y
12
-inhibitor.
Demographic and clinical characteristics
The baseline characteristics are presented in Table 1. 
 Compared with patients on clopidogrel, those on prasugrel 
were substantially younger, more likely men, and less often 
had a history of stroke or TIAs. Further, patients on prasugrel 
less often had a history of myocardial infarction (MI) or PCI, 
peripheral vascular disease, congestive heart failure, chronic 
renal impairment, or diabetes  mellitus. However, the number 
of diseased vessels as well as the distribution of infarct-related 
artery were similar (left main coronary artery and left anterior 
descending artery 42.7% vs 41.6%), but time from symptom 
onset to PCI was 18 minutes shorter in the prasugrel group.
Mortality at 1-year follow-up
In the primary analysis grouping patients by the P2Y
12
-
 inhibitor used from the prehospital LD until hospital dis-
charge, a total of 49 deaths occurred, ten during the hospital 
stay and an additional 39 during follow-up. Twenty-two 
deaths were classified as CV death, 16 as non-CV death, and 
eleven were not further specified. The CV deaths occurred 
in four patients (0.5%) on prasugrel, in eleven patients 
(2.6%) on clopidogrel, in three patients (0.6%) switched 
from  clopidogrel to prasugrel (Figure 2), and in four patients 
(1.6%) treated with other regimens (“other” group).
The adjusted OR for prasugrel patients compared with 
clopidogrel patients for CV death was 0.248, 95% CI 
0.069–0.893; for death from any cause OR 0.605, 95% CI 
0.263–1.391; and for presumed CV death, OR 0.416, 95% 
CI 0.155–1.115.
For the group of patients who switched during the initial 
hospitalization from clopidogrel to prasugrel, compared with 
those who stayed on clopidogrel, the adjusted OR for CV 
death was 0.227 (95% CI 0.050–1.038; Figure 3); for death 
from any cause OR 0.235 (95% CI 0.065–0.847); and for 
presumed CV death OR 0.253 (95% CI 0.068–0.939).
 
Va
sc
ul
ar
 H
ea
lth
 a
nd
 R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
26
-J
an
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Vascular health and risk Management 2016:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
147
Mortality in primary angioplasty patients on upstream P2Y12 inhibitors
Mortality analysis based on discharge 
medication
This secondary analysis grouped patients by the P2Y
12
-
inhibitor prescribed at discharge, thus capturing only the 
39 deaths that occurred between discharge and the 1-year 
follow-up. The patient disposition is presented in Figure 4, 
and the baseline characteristics in Table 2.
The CV deaths occurred in 0.2% of patients discharged on 
prasugrel and in 1.4% of patients discharged on  clopidogrel. 
The adjusted OR for prasugrel patients compared with 
 clopidogrel patients for CV death was 0.121 (95% CI 
0.026–0.563; Figure 5); for death from any cause OR 0.412 
(95% CI 0.167–1.016); and for presumed CV death OR 0.306 
(95% CI 0.104–0.906).
For patients discharged on ticagrelor, the rates of CV 
death, all-cause death, and presumed CV death were 1.3%, 
3.8%, and 1.9%, respectively. Patients who were discharged 
without a P2Y
12
-inhibitor experienced CV death in 2.9%, 
all-cause death in 5.7%, and presumed CV death in 2.9%.
Discussion
The MULTIPRAC registry was launched in 2011 when 
many STEMI networks used prehospital DAPT, including 
clopidogrel, as an established practice in order to provide 
antiplatelet therapy as soon as possible, as stated in the 
guidelines. This was done to prepare STEMI patients for 
primary PCI and this practice was implemented despite a lack 
of evidence from formal testing. The introduction of newly 
CV death
CV death
Favors prasugrel*
Favors prasugrel
0.0 0.5 1 1.5 2.0
0.0 0.5 1 1.5 2.0
Prasugrel
(n=824)
Switch from
clopidogrel to
prasugrel
(n=544)
Clopidogrel
(n=425)
Clopidogrel
(n=425)
Odds ratio
Odds ratio
Adjusted 95%
confidence interval
Adjusted 95%
confidence interval
4 (0.5%)
3 (0.6%)
11 (2.6%)
11 (2.6%) 0.227 0.050–1.038
0.248 0.069–0.893
Favors clopidogrel
 Favors clopidogrel
Figure 3 cV death from hospital admission through 1 year by P2Y12-inhibitor treatment.
Notes: *Switched from clopidogrel. Confidence intervals were adjusted for differences in baseline characteristics. Data are based on linear regression model.
Abbreviation: cV, cardiovascular.
Enrolled
n=2,095
Eligible for analysis
n=2,052b
At discharge
n=2,042
In-hospital death n=10
Excluded from analysis
n=43a
Informed consent
withdrawn n=1
Lost to follow-up n=15Eligible for 1-year mortality follow-up
n=2,026
Prasugrel at
discharge
n=1,344 (66.3%)
Clopidogrel at
discharge
n=491 (24.2%)
Ticagrelor at
discharge
n=156 (7.7%)
No P2Y12-inhibitor at
discharge
n=35 (1.7%)
Figure 4 Patient disposition by P2Y12-inhibitor prescribed at hospital discharge.
Notes: aThirty-one missed loading dose, ten received loading dose in catheterization laboratory, one vomited after loading dose, one had no initial sTeMi diagnosis. bDifferent 
from baseline data reported earlier, as one patient needed to be withdrawn (informed consent form was lost).
Abbreviation: sTeMi, sT-elevation myocardial infarction.
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available prasugrel into such strategy, and the associated 
clinical outcomes for the initial hospitalization have been 
reported from MULTIPRAC earlier.8 We did not find sig-
nificant differences in the rates of major adverse cardiac and 
cerebrovascular events when comparing patients treated with 
clopidogrel or prasugrel (1.6% vs 2.3%), even when adjusting 
for baseline characteristics. In-hospital CV death rate was 
below 1%, rendering adjustment for CV death impossible 
due to the small number of events. In the present prespeci-
fied analysis, including the 1-year follow-up, a 2.1% absolute 
difference in CV mortality emerged, favoring prasugrel over 
clopidogrel. We focused on long-term mortality because it is 
a hard endpoint, independent from trial-specific definitions, 
and is an integral measure of both potential areas of impact 
Table 2 Baseline characteristics by P2Y12-inhibitor treatment prescribed at hospital discharge
Characteristic All patients, 
n=2,026  
(100.0%)
Prasugrel, 
n=1,344  
(66.3%)
Clopidogrel, 
n=491  
(24.2%)
Ticagrelor, 
n=156  
(7.7%)
P-value,  
prasugrel vs 
clopidogrel
age, years, mean (sD) 60.8 (12.0) 57.5 (10.1) 66.5 (13.1) 70.2 (11.6) ,0.001a
sex, female 442 (21.8) 235 (17.5) 158 (32.2) 43 (27.6) ,0.001b
Previous Mi 225 (11.1) 130 (9.7) 70 (14.3) 22 (14.1) 0.006b
congestive heart failure 44 (2.2) 22 (1.6) 15 (3.1) 6 (3.8) 0.060b
Previous Pci 183 (9.0) 106 (7.9) 56 (11.4) 18 (11.5) 0.019b
Previous caBg 29 (1.4) 12 (0.9) 12 (2.4) 5 (3.2) 0.013b
Previous stroke/Tia 82 (4.0) 14 (1.0) 43 (8.8) 21 (13.5) ,0.001b
Peripheral vascular disease 79 (3.9) 31 (2.3) 32 (6.5) 15 (9.6) ,0.001b
chronic renal impairment 31 (1.5) 10 (0.7) 16 (3.3) 4 (2.6) ,0.001b
Diabetes mellitus 271 (13.4) 169 (12.6) 76 (15.5) 21 (13.5) 0.106b
Killip class $ iic 108 (7.1) 60 (5.9) 33 (9.6) 11 (7.8) 0.022b
Time from sO to start of Pci, 
median (hh:mm)
3:15 3:07 3:30 2:54 0.001d
Time from isD to start of Pci, 
median (hh:mm)
1:28 1:28 1:32 1:23 0.933d
no of diseased vessels ($2) 913 (45.1) 576 (42.9) 248 (50.5) 73 (46.8) 0.004b
ira (lMca or laD) 878 (43.3) 584 (43.5) 204 (41.5) 72 (46.2) 0.467b
Notes: Values are n (%) if not stated otherwise. P-values refer to the comparison between the clopidogrel vs prasugrel groups. at-test, blogistic regression model, cinformation 
available from 1,528 patients, and dWilcoxon signed rank test.
Abbreviations: caBg, coronary artery bypass graft; hh:mm, hours:minutes; ira, infarct-related artery; isD, initial sTeMi diagnosis; laD, left anterior descending coronary 
artery; lMca, left main coronary artery; Mi, myocardial infarction; Pci, percutaneous coronary intervention; sD, standard deviation; sO, symptom onset; Tia, transient 
ischemic attack.
Prasugrel versus clopidogrel
Ticagrelor versus clopidogrel
Favors prasugrel Favors clopidogrel
0.0 0.5 1 1.5 2.0
0.0 0.5 1 1.5 2.0 2.5 3.0 3.5 4.0 4.5
CV death
CV death
Ticagrelor
(n=156)
Prasugrel
(n=1,344)
Clopidogrel
(n=491)
Clopidogrel
(n=491)
Odds ratio
Odds ratio
Adjusted 95%
confidence interval
Adjusted 95%
confidence interval
0.136–4.6740.7967 (1.4%)2 (1.3%)
3 (0.2%) 7 (1.4%) 0.121 0.026–0.563
Favors ticagrelor Favors clopidogrel
Figure 5 cV death from hospital discharge to 1-year follow-up by P2Y12-inhibitor prescribed at hospital discharge.
Notes: Confidence intervals were adjusted for differences in baseline characteristics. Data are based on linear regression model.
Abbreviation: cV, cardiovascular.
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from antiplatelet medications: reduction in ischemic events 
and increase in bleeding events (and respective sequelae). 
Furthermore, when available, looking at CV mortality is 
preferable, as it excludes other reasons for death that would 
reduce power when comparing antiplatelet medications.
A similar mortality pattern to that observed in MULTI-
PRAC – with no significant predischarge difference in mortal-
ity but a significant long-term benefit – was previously reported 
from a single center experience in the UK,9 comparing prasu-
grel and clopidogrel started in-hospital. The 1-year all-cause 
mortality rate was 4.5% in the clopidogrel group (n=822) but 
significantly lower, 2.8%, in the prasugrel group (n=866).
Such a pattern is compatible with the concept that long-
term mortality in patients post-STEMI may be a consequence 
of the initial MI or be attributable to recurrent platelet- mediated 
ischemic events (new MI, stent thrombosis). One other 
important contributor to mortality, which is also influenced by 
antiplatelet medication, is bleeding.10 The event rates for re-MI 
(0.1% and 0.2%) or major bleeding requiring transfusions 
(0.5% and 1.2%) for the in-hospital phase of  MULTIPRAC are 
low with prasugrel or clopidogrel, respectively.8 These differ-
ences, though small, would favor a later mortality benefit with 
prasugrel. To what extent the observed slightly shorter delay 
from symptom onset to PCI in the prasugrel and switching 
groups has impacted the observed mortality rates is unclear. 
Time periods from diagnosis to PCI were similar in all three 
groups. Additional postdischarge suppression of an accumula-
tion of re-MIs with prasugrel as compared to  clopidogrel has 
been reported previously from the TRITON-TIMI 38 study,11,12 
while the increased  bleeding rate was mitigated when applying 
label restrictions for use.13
Today’s in-hospital mortality rate associated with STEMI 
treated with primary PCI is quite low. Because of this low 
rate, large samples are required to demonstrate differences 
between treatments. Therefore, it is interesting that the larger 
Acute Myocardial Infarction in Switzerland (AMIS Plus) 
Registry propensity score matched-pairs analysis, including 
4,602 patients from Switzerland, found significantly lower 
in-hospital mortality with prasugrel (1.8%) vs clopidogrel 
(3.1%).14 That study, which included 70% STEMI patients, 
did not report adjusted 1-year mortality data.
Similar results have been reported from another, albeit 
smaller, Swiss registry15 reporting both in-hospital and long-term 
CV mortality for an acute coronary syndrome (ACS) popula-
tion treated with prasugrel (n=756; 88% STEMI) or clopidogrel 
(n=1,392; 42% STEMI). They found a trend toward a lower in-
hospital (0.5% vs 1.9%) and 1-year (2.6% vs 4.2%) mortality 
rate associated with prasugrel compared with clopidogrel.
In an unadjusted analysis from the large Swedish SCAAR 
registry, the 1,265 STEMI patients treated with prasugrel had 
a lower 30-day all-cause mortality rate compared with the 
5,880 patients treated with clopidogrel (2.5% vs 5.0%).16 The 
age difference (with higher age being related to increased 
mortality) between prasugrel and clopidogrel patients was 
only 2 years and therefore not the likely cause of the sub-
stantial difference in outcomes.
The corresponding RCTs comparing the new P2Y
12
-
inhibitors prasugrel or ticagrelor versus clopidogrel are 
TRITON-TIMI 38 and PLATO. For the respective full ACS 
study-populations and the composite primary endpoints at 
study end, both studies reported the newer P2Y
12
-inhibitors 
to be superior to clopidogrel.11,17 Data from the primary 
PCI sub-group (n=2,340) in TRITON-TIMI 38 comparing 
prasugrel with clopidogrel, where the two P2Y
12
-inhibitors 
were started in-hospital, showed a significant absolute 1.3% 
reduction in 30-day CV death rate with prasugrel compared 
with clopidogrel (1.2% vs 2.5%, P=0.03).18 At 15-month 
follow-up, this difference stayed within the same order of 
magnitude, though it was no longer significant (P=0.09). 
A previous report from the PLATO study showed that, for a 
large mixed STEMI population (n=7.544) including 2,105 
patients not treated with primary PCI, there was no differ-
ence in early mortality between ticagrelor and clopidogrel. 
 However, there was a trend toward lower CV mortality 
at 1 year (difference 1%, P=0.07) for ticagrelor versus 
clopidogrel.19 Recently, the outcomes for the primary PCI 
cohort from PLATO (n=4,949) were disclosed.20 In this first 
reported sub-group from the PLATO study, in which patients 
were treated with PCI only, similar 1-year CV mortality 
was reported for ticagrelor and clopidogrel (3.7% vs 4.0%, 
P=0.67).
Extending the view beyond STEMI, pretreatment 
with newer and faster acting oral P2Y
12
-inhibitors in ACS 
patients destined for invasive evaluation has recently 
been challenged in two larger RCTs (ATLANTIC7 and 
ACCOAST21). Both failed to show an improvement with 
pretreatment in terms of standard ischemic endpoints. It 
could be interpreted that pretreatment is of little impor-
tance when 1) the time difference between pretreatment 
and treatment at the time of PCI is short; 2) there is fast 
access to PCI; and 3) patients are treated with a potent 
P2Y
12
-inhibitor, that is, prasugrel or ticagrelor. In the case 
of the ATLANTIC study, the results, including no observed 
difference in bleeding, may be explained by the extremely 
short duration of pretreatment (,1 hour) in the STEMI 
population studied. In contrast, when the P2Y
12
-inhibitor 
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was applied sufficiently early to establish substantial plate-
let inhibition at the time of vascular access and PCI, such 
as in the non-STEMI population studied in ACCOAST, 
additional bleeding events were observed with pretreat-
ment. However, whereas, clopidogrel was included in the 
MULTIPRAC registry, it was not included as a comparator 
in the ATLANTIC and ACCOAST studies. In our real world 
STEMI population, during the hospital-phase rates of major 
bleeding were low in all treatment groups.8 This deserves 
particular emphasis, as all our patients started the respec-
tive P2Y
12
-inhibitor prior to reaching the catheterization 
laboratory, and frequent early switching from clopidogrel 
to prasugrel with or without a LD was observed.
Limitations
Due to the difference in the labels of prasugrel and clopi-
dogrel, the groups differed significantly in baseline char-
acteristics. When performing multivariate adjustment for 
differences in baseline characteristics, potential confounders 
may not all have been accounted for. The P2Y
12
-inhibitors 
taken after hospital discharge were not monitored, and 
therefore true long-term exposure to these agents cannot be 
quantified. However, experience shows that the antiplatelet 
medication prescribed at discharge is rarely changed in the 
outpatient setting; it is more often stopped than switched, for 
example, when bleeding occurs. According to an intention-
to-treat approach, for our analyses we assumed that patients 
continued to take the P2Y
12
-inhibitor at discharge for the 
duration of follow-up. Mortality analyses were based on 
relatively small numbers of deaths. The fact that only patients 
who could take oral medications prehospital were eligible 
for enrollment in MULTIPRAC excluded the most severely 
ill patients, which resulted in a study population at quite 
low risk of death as compared to fully unselected primary 
angioplasty populations.
No information on bleeding events following discharge 
from the initial hospitalization is available.
Summary and conclusion
In MULTIPRAC, patients from routine practice undergoing 
primary angioplasty, who were able to start oral antiplatelet 
therapy prehospital, treatment with prasugrel as compared to 
clopidogrel was associated with a lower risk of CV death at 
1-year follow-up. This is in line with the results from other 
registries and the randomized controlled study TRITON-TIMI 
38. It supports the preferential recommendation of prasugrel 
over clopidogrel according to the latest European Society for 
Cardiology guidelines.
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